In general, antidepressants function by increasing the availability of monoamines (serotonin, noradrenaline, and/or dopamine) in the synapse; these monoamines are thought to be depleted in depression.1
- SSRIs, SNRIs and TCAs achieve this by blocking one or more of the monoamine transporters, thus preventing the neurotransmitters from being taken back into the axon terminal that released them.1
- MAOIs achieve this by inhibiting the activity of the monoamine oxidase enzyme (acting as an ‘enzyme inhibitor’) and thus preventing the breakdown of neurotransmitters.1
MAOI=monoamine oxidase inhibitor; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin–noradrenaline reuptake inhibitor; TCA=tricyclic antidepressant.
Related content
Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder (MDD) who fail to respond to at least two adequate antidepressant trials.
Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.
Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.